The Company announced the development of the first antiviral to combat BK virus, one of the most common viral infections in transplant patients CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics ...
Orthogon’s small molecule therapeutics redefine treatment possibilities for BK virus infections. CANTON, Mass.–(BUSINESS WIRE)–December 10, 2024– Orthogon Therapeutics, a developer of novel antiviral ...
Presenter: Jonathan Barratt, Ph.D., FRCP, The Mayer Professor of Renal Medicine, University of Leicester, U.K. About MAU868 MAU868, a first-in-class monoclonal antibody, has the potential to ...
Single-cell analysis helps uncover how the BK virus replicates, opening the door to new drug targets. BK polyomavirus (BKPyV) is a major cause of kidney transplant failure. Without a complete ...
A virus that 95% of adults carry from childhood infections may be initiating bladder cancer decades later, according to research from the University of York and collaborating institutions. BK ...
Research published in the Journal of Infection investigated the use of metagenomic next-generation sequencing (mNGS) in diagnosing bloodstream infections (BSIs) for immunocompromised hematology ...
CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics, a developer of novel antiviral medicines, today announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results